HEALTHJun 6 · 00:00 UTCSCMP CHINAJulie Zhang

Targeting US$610 billion longevity market, biotech firms race to reverse ageing

Biotech firms are targeting a US$610 billion longevity market to reverse aging by using AI to reprogram human cells, according to Beijing-based METiS TechBio CEO Lai Tsai-ta. The approach involves fixing errors in genetic code, such as DNA sequences, and potentially repairing immune cells like T cells to slow or reverse the aging process.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

METiS TechBioorganizationLai Tsai-tapersonAItopiclongevity markettopicT cellstopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

TECHNOLOGYJun 6 · 00:00 UTC
Targeting US$610 billion longevity market, biotech firms race to reverse ageing
HEALTHApr 12 · 05:06 UTC
Method to reverse cellular ageing is about to be tested in humans
HEALTHApr 7 · 00:00 UTC
This method to reverse cellular ageing is about to be tested in humans
SCIENCEMay 27 · 14:18 UTC
In step toward immortality, Israeli scientists say they can ‘rewind’ aging in mouse livers
SCIENCEMay 12 · 23:30 UTC
Scientists make old blood stem cells young again in major anti-aging breakthrough
HEALTHApr 9 · 00:00 UTC
Daily briefing: A treatment to reverse cellular ageing is about to be tested in people